TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20194956

Group type: EXPERIMENTAL
Intervention: Daily isokinetic hamstring exercises starting at postoperative 3 weeks (group I)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Daily isokinetic hamstring exercises starting at postoperative 9 weeks (group II)
Number of subjects: 48
Study: 18343263

Group type: EXPERIMENTAL
Intervention: ER‐DP+ASA 200/25 mg BID
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/d plus ASA 81 mg/d
Number of subjects: 60
Study: 17146312

Group type: EXPERIMENTAL
Intervention: Strength-training
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Endurance-training
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 12701778

Group type: EXPERIMENTAL
Intervention: 1 ml of Depo‐Medrol (40 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1 ml of sterile saline placebo (control)
Number of subjects: 40
Study: 11088092

Group type: EXPERIMENTAL
Intervention: Silver-coated catheters
Number of subjects: 27878

Group type: COMPARATOR
Intervention: Uncoated catheters
Number of subjects: 27878
Study: 9372647

Group type: COMPARATOR
Intervention: Prednisone 20 mg/d in a prospectively tapered regimen (P)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination therapy with prednisone 20 mg/d and cyclosporin A 5 to 7 mg/kg/d (P-CsA)
Number of subjects: 37
Study: 1552108

Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3005774

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen 20 mg/m2 Days 2-6 and premarin 0.625 mg Q 12-H X 3 on Day 7
Number of subjects: 110

Group type: COMPARATOR
Intervention: Chemotherapy without additional hormones
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen and premarin in patients with inflammatory breast cancer
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen and premarin
Number of subjects: 110
Study: 30388714

Group type: EXPERIMENTAL
Intervention: 80 mg methylprednisolone
Number of subjects: 116

Group type: COMPARATOR
Intervention: Preservative-free normal saline (placebo)
Number of subjects: 116
Study: 28341722

Group type: EXPERIMENTAL
Intervention: BUPI (bupivacaine 0.46%, 0.46 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BUPI-DEX (bupivacaine with dexmedetomidine 1 µg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BUPI-BUPRE (bupivacaine with buprenorphine 2.5 µg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: CONTROL (saline)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BUPI
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BUPI-DEX
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BUPI-BUPRE
Number of subjects: 6
Study: 25442243

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid 2000/125 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 24135322

Group type: EXPERIMENTAL
Intervention: Dalcetrapib (RO4607381)
Number of subjects: 130
Study: 21768544

Group type: EXPERIMENTAL
Intervention: 10 mg/d ezetimibe + 2.5 g phytosterols
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 10 mg/d ezetimibe + phytosterol placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ezetimibe placebo + phytosterol placebo
Number of subjects: 21
Study: 19451666

Group type: EXPERIMENTAL
Intervention: Supervised Greek traditional dance classes for 10 weeks (1 hr, 2 sessions/week, n = 14)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 26
Study: 16403107

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 40
Study: 14716792

Group type: EXPERIMENTAL
Intervention: Lightweight composite multifilament mesh (polypropylene 27‐30 g/m(2))
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional densely woven polypropylene mesh (100‐110 g/m(2))
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 122
Study: 11385124

Group type: EXPERIMENTAL
Intervention: Traffic wardens (outdoor workers)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Office workers
Number of subjects: 99

Group type: COMPARATOR
Intervention: Environmental monitoring
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Blood benzene
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 1-hydroxypyrene and trans-muconic acid excretion
Number of subjects: 99
Study: 9028693

Group type: COMPARATOR
Intervention: Standard 16‐week group behavioral weight‐control program
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Standard 16‐week group behavioral weight‐control program with three individualized motivational interviewing sessions
Number of subjects: 22
Study: 8398224

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic interventions (specific interventions not detailed in the abstract)
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: Direct mailings and work site screenings (strategies for recruitment)
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: Cohort or wave type of enrollment
Number of subjects: 2182
Study: 3780685

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Alizapride 100 mg
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Alizapride 200 mg
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 182

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 182
Study: 31900543

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 29383894

Group type: EXPERIMENTAL
Intervention: High intensity TEAS (10 mA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low intensity TEAS (5 mA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (0 mA)
Number of subjects: 150
Study: 26725257

Group type: EXPERIMENTAL
Intervention: T1DM patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (NC)
Number of subjects: 30
Study: 25366037

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glibenclamide (5 to 10 mg twice daily)
Number of subjects: 20
Study: 22504188

Group type: EXPERIMENTAL
Intervention: HAL/THD procedure without Doppler transducer (non-Doppler group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional HAL/THD procedure (Doppler group)
Number of subjects: 82
Study: 19935091

Group type: EXPERIMENTAL
Intervention: c‐pharm early (sertraline at 150 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: c‐pharm late (placebo initially, then sertraline at 150 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18035205

Group type: EXPERIMENTAL
Intervention: THC/CBD oromucosal spray (27 mg/mL: 25 mg/mL)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 16198887

Group type: EXPERIMENTAL
Intervention: LBBB group (n = 40) with LVEF < 50%
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: LBBB group (n = 40) with LVEF >= 50%
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: LBBB group (n = 40)
Number of subjects: 89

Group type: COMPARATOR
Intervention: RV pacing group (n = 26)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 89
Study: 12242979

Group type: EXPERIMENTAL
Intervention: Gastric pacing
Number of subjects: 0
Study: 10419245

Group type: EXPERIMENTAL
Intervention: Ibuprofen to prevent recurrent febrile seizures
Number of subjects: 230
Study: 7477928

Group type: EXPERIMENTAL
Intervention: Sinusoidal tilts (frequency 0.007 Hz, amplitude 1.5 degrees)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramp tilts (amplitude 1.0 and 0.25 degrees, angular velocity 0.04 degrees/s)
Number of subjects: 0
Study: 2405131

Group type: EXPERIMENTAL
Intervention: 1,25‐dihydroxyvitamin D
Number of subjects: 108

Group type: COMPARATOR
Intervention: dihydrotachysterol
Number of subjects: 108
Study: 6932833

Group type: EXPERIMENTAL
Intervention: Prazosin 5 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Prazosin therapy (4 weeks)
Number of subjects: 11
Study: 31558478

Group type: EXPERIMENTAL
Intervention: MET141 low-risk subgroup (lowest 25th percentile of scores)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: MET141 low-risk patients in the METABRIC cohort
Number of subjects: 454
Study: 29082755

Group type: EXPERIMENTAL
Intervention: compression stockings group
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: full‐leg compression group
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: shorts group
Number of subjects: 18

Group type: COMPARATOR
Intervention: control (no compression garments)
Number of subjects: 18
Study: 27382104

Group type: EXPERIMENTAL
Intervention: CHOP8
Number of subjects: 364

Group type: COMPARATOR
Intervention: CHOP3RT
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Rituximab + CHOP3RT (S0014)
Number of subjects: 364
Study: 24777901

Group type: EXPERIMENTAL
Intervention: Resident Antimicrobial Management Plan (RAMP)
Number of subjects: 1628

Group type: COMPARATOR
Intervention: Control group (no RAMP)
Number of subjects: 1628
Study: 22779383

Group type: EXPERIMENTAL
Intervention: Fluoridated milk (0.5 mgF per 189 ml carton)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fluoridated milk (0.9 mgF per 189 ml carton)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-fluoridated milk
Number of subjects: 50
Study: 19718394

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg daily)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Alfacalcidol (1 microg daily)
Number of subjects: 112
Study: 17167264

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (group A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-fluoride dentifrice (group B)
Number of subjects: 10
Study: 15103313

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 4287

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 4287
Study: 12366499

Group type: EXPERIMENTAL
Intervention: Global haemostatic tests (INR and APTT)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Prolonged APTT
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (patients not fulfilling laboratory criteria)
Number of subjects: 184
Study: 10194484

Group type: EXPERIMENTAL
Intervention: Stripping of the long saphenous vein
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saphenofemoral ligation alone
Number of subjects: 100
Study: 7790946

Group type: EXPERIMENTAL
Intervention: Buprenorphine (6 or 12 mg daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2134443

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (MP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (without steroid drug)
Number of subjects: 43
Study: 340326

Group type: EXPERIMENTAL
Intervention: Cimetidine (1200 mg per day for 6 weeks)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 85
Study: 30573503

Group type: EXPERIMENTAL
Intervention: Obinutuzumab-based immunochemotherapy
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Rituximab-based immunochemotherapy
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 1202
Study: 27642816

Group type: EXPERIMENTAL
Intervention: Midline cortical bone trajectory (CBT) pedicle screws in outpatient surgery center (OSC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional pedicle screws in hospital
Number of subjects: 60
Study: 25842271

Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 987

Group type: COMPARATOR
Intervention: Standard arm (in-clinic visits)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Remote monitoring among CRT-D recipients
Number of subjects: 987

Group type: COMPARATOR
Intervention: Standard arm among CRT-D recipients
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Remote monitoring among ICD patients
Number of subjects: 987

Group type: COMPARATOR
Intervention: Standard arm among ICD patients
Number of subjects: 987
Study: 24088689

Group type: EXPERIMENTAL
Intervention: Family planning educational intervention videos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive family planning services
Number of subjects: 0
Study: 21059626

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 3g/day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 19016720

Group type: EXPERIMENTAL
Intervention: Romiplostim therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17996996

Group type: EXPERIMENTAL
Intervention: Hib-MenCY-TT co-administered with DTPa-HBV-IPV and PCV7
Number of subjects: 0
Study: 15249851

Group type: EXPERIMENTAL
Intervention: Structured intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Counseling AI (control group)
Number of subjects: 39
Study: 14749690

Group type: EXPERIMENTAL
Intervention: Buprenorphine 8 mg daily
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Buprenorphine 16 mg daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 10077717

Group type: EXPERIMENTAL
Intervention: Hypnosis and self-hypnosis administered and taught by nurses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (instrumental and pharmacological management of chronic pain)
Number of subjects: 0
Study: 7719273

Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination (SDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2038044

Group type: EXPERIMENTAL
Intervention: Appraisal of Diabetes Scale (ADS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Additional measures of diabetes-related health beliefs, diabetic daily hassles, perceived stress, diabetic adherence, and psychiatric symptoms
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ADS on two additional occasions
Number of subjects: 200
Study: 7196467

Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term antihypertensive treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure at home
Number of subjects: 0
Study: 31888706

Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 800

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 800
Study: 28402128

Group type: EXPERIMENTAL
Intervention: Skeletally anchored Class II elastics
Number of subjects: 12

Group type: COMPARATOR
Intervention: Monobloc appliance
Number of subjects: 12
Study: 26404990

Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL) by BDS5 peer tutors
Number of subjects: 2

Group type: COMPARATOR
Intervention: Staff-led groups
Number of subjects: 2
Study: 24215306

Group type: EXPERIMENTAL
Intervention: Community screening and treatment of asymptomatic carriers of P. falciparum
Number of subjects: 13767

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 13767
Study: 21415174

Group type: EXPERIMENTAL
Intervention: Constant-P tests
Number of subjects: 14
Study: 19716683

Group type: EXPERIMENTAL
Intervention: Atomoxetine (up to 1.2 mg/kg/day)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Atomoxetine and Placebo
Number of subjects: 139
Study: 17355270

Group type: EXPERIMENTAL
Intervention: External cephalic version
Number of subjects: 805
Study: 15274379

Group type: EXPERIMENTAL
Intervention: Preoperative whole-liver chemolipiodolization
Number of subjects: 59

Group type: COMPARATOR
Intervention: Preoperative selective chemolipiodolization
Number of subjects: 59
Study: 11405286

Group type: EXPERIMENTAL
Intervention: 30 mg risedronate as a tablet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 30 mg risedronate as an aqueous solution
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 0.3 mg risedronate as an intravenous infusion
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oral administration
Number of subjects: 33
Study: 9563277

Group type: EXPERIMENTAL
Intervention: Controlled diabetes in scleredema patients with diabetes (5 out of 11 patients showed improvement)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Scleredema without diabetes (8 out of 10 patients)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Facial involvement in scleredema patients without diabetes
Number of subjects: 21
Study: 7812419

Group type: EXPERIMENTAL
Intervention: Predictive equation group using computed tomography (CT) for adipose tissue areas at the L4-L5 level.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Measured adipose tissue areas by CT.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Single best predictors of measured adipose tissue areas.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Simple and safe anthropometric measurements.
Number of subjects: 93
Study: 29133948

Group type: EXPERIMENTAL
Intervention: Anti-depressant medications (ADMs): escitalopram, sertraline, or venlafaxine-extended release for 8 weeks
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 202
Study: 27863515

Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+), delivered by community health workers, n = 35
Number of subjects: 70

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU), n = 35
Number of subjects: 70
Study: 25337750

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 508

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 508
Study: 23778061

Group type: EXPERIMENTAL
Intervention: Health education interventions targeting specific populations among Ahmedabad urban slum dwellers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heat exposure and vulnerability factors
Number of subjects: 0
Study: 20177974

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BPN/NLX)
Number of subjects: 69
Study: 18547268

Group type: EXPERIMENTAL
Intervention: Coordinated headache management program (class on headache types, triggers, treatment options; diagnosis and treatment by trained professional; proactive follow-up by case manager) for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care from primary care providers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coordinated headache management program
Number of subjects: 0
Study: 16988115

Group type: EXPERIMENTAL
Intervention: PSY+PS cookie (7.68 g/d PSY and 2.6 g/d PS)
Number of subjects: 33
Study: 14574660

Group type: EXPERIMENTAL
Intervention: BUN >= 15 mg/dL (sensitive cutpoint)
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: BUN >= 20 mg/dL (high-yield cutpoint)
Number of subjects: 7000
Study: 10937315

Group type: EXPERIMENTAL
Intervention: Trust in automation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trust in human partners
Number of subjects: 0
Study: 8957978

Group type: EXPERIMENTAL
Intervention: Midlatency auditory evoked potentials (MLAEP)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combination of EEG, MLAEP, MAP and T measures
Number of subjects: 41
Study: 1551309

Group type: EXPERIMENTAL
Intervention: Rice (50 g carbohydrate) eaten as part of a mixed meal (32 g protein, 20 g fat)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glucose (50 g carbohydrate) eaten as part of a mixed meal (32 g protein, 20 g fat)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rice (50 g carbohydrate) eaten alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glucose (50 g carbohydrate) eaten alone
Number of subjects: 30
Study: 4025172

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination therapy (Propranolol + Hydralazine)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Diuretic-only therapy
Number of subjects: 9
Study: 30993499

Group type: EXPERIMENTAL
Intervention: Single-Session Intervention (SSI) teaching growth mindset
Number of subjects: 96
Study: 29444682

Group type: EXPERIMENTAL
Intervention: IgG subclass deficiency (IgG1 < 2.8 g/L; IgG2 < 1.15 g/L) in MACRO cohort
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: IgG subclass deficiency (IgG1 < 2.8 g/L; IgG2 < 1.15 g/L) in STATCOPE cohort
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: IgG3 and IgG4 levels
Number of subjects: 1629
Study: 26808817

Group type: EXPERIMENTAL
Intervention: SUMMIT
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: SUMMIT-PERSON
Number of subjects: 232

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 232
Study: 25531993

Group type: EXPERIMENTAL
Intervention: RMB (Rabeprazole/Rifabutin/Minocycline/Bismuth sub‐citrate) for 10 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: MTB (Rabeprazole/Tinidazole/Minocycline/Bismuth sub‐citrate) for 10 days
Number of subjects: 54
Study: 22983782

Group type: EXPERIMENTAL
Intervention: Functional electrical muscle stimulation‐assisted supine cycling on one leg while the other leg undergoes cycling alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study: 19963333

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly for 8 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19016075

Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp) 0.06 IU/kg BW
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16129614

Group type: EXPERIMENTAL
Intervention: Combination of tube thoracostomy and streptokinase instillation (group B)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Sole tube thoracostomy (group A)
Number of subjects: 127
Study: 12145004

Group type: EXPERIMENTAL
Intervention: SE-enriched spread (18.2 +/- 1.5 g SE spread/d, corresponding to 1.60 +/- 0.13 g SEs)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: SE-enriched spread
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control spread
Number of subjects: 38
Study: 10456525

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/day subcutaneous recombinant human growth hormone (rhGH)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 7541782

Group type: EXPERIMENTAL
Intervention: Mapping-enhanced counseling
Number of subjects: 331

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 331